**Question:** INH can be used safely in the presence of

A. tuberculosis
B. other anti-tuberculosis drugs
C. isoniazid resistance
D. rifampicin resistance

**Core Concept:**

Isoniazid (INH) is an essential drug in the treatment of tuberculosis, a bacterial infection caused by Mycobacterium tuberculosis. It is a prodrug that is converted into its active form, hydrazine, by liver enzymes, specifically acetyl-CoA acetylhydrazine synthetase. The drug works by inhibiting mycobacterial enzymes involved in the synthesis of mycolic acids, which are essential for bacterial cell wall synthesis.

**Why the Correct Answer is Right:**

INH can be used safely in the presence of other anti-tuberculosis drugs because they work synergistically to target different aspects of the mycobacterial cell wall synthesis. For example, rifampicin inhibits DNA-dependent RNA polymerase, preventing the bacteria from producing RNA and thus affecting protein synthesis. These combinations enhance the overall effectiveness of the treatment and reduce the likelihood of drug resistance development.

**Why Each Wrong Option is Incorrect:**

A. INH cannot be used safely in the presence of tuberculosis itself (Option A) as it is the indication for its use. However, it is essential to consider potential drug interactions and co-infections when selecting an appropriate treatment regimen.

B. Although other anti-tuberculosis drugs may be used in combination with INH, their use does not justify the safety of using INH alone in the presence of tuberculosis (Option B).

C. Isoniazid resistance (Option C) refers to a bacterial strain that is resistant to INH, not a condition in the patient. Resistance is a concern when considering the choice of treatment regimen, but does not directly address the safety of using INH in combination with other drugs.

D. Rifampicin resistance (Option D) is a concern when selecting an appropriate treatment regimen, as it indicates resistance to rifampicin, one of the essential drugs in the standard WHO-recommended regimen. Combining INH with rifampicin-resistant tuberculosis may lead to treatment failure and may contribute to the development of drug-resistant strains.

**Clinical Pearl:**

Co-administration of INH with other essential anti-tuberculosis drugs (rifampicin, pyrazinamide, ethambutol, and streptomycin) is recommended in the standard WHO-recommended regimen for treating tuberculosis. This combination ensures effective antimicrobial activity against M. tuberculosis and reduces the likelihood of drug resistance development.